



Marksans Pharma Ltd.

Date: 31st May, 2023

BSE Limited

Corporate Relation Department
Phiroze Jeejeeboi Towers,
Dalal Street,
Mumbai - 400001.
Scrip Code: 524404

National Stock Exchange of India Limited

Listing Department
Exchange Plaza, C-1, Block-G,
Bandra-Kurla Complex,
Bandra (East), Mumbai - 400051.
Symbol: MARKSANS

Sub: Newspaper Publication

Dear Sir,

Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclosed herewith copies of audited financial results of the Company for the quarter and year ended March 31, 2023 published on May 31, 2023 in the Business Standard (English) and Lakshadeep (Marathi) newspapers.

You are requested to note the above in your records.

Thanking You.

Yours faithfully,
For **Marksans Pharma Limited**

Harshavardhan Panigrahi
Company Secretary

Encl: As above

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara,
Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • E-mail: info@marksanspharma.com
www.marksanspharma.com

NAGA DHUNSERI GROUP LIMITED										
REGD. OFFICE : " DHUNSERI HOUSE ", 4A, WOODBURN PARK, KOLKATA - 700 020.										
CIN - L01132WB1918PLC003029; Website : www.nagadhunserigroup.com; E-mail : mail@nagadhunserigroup.com; Phone : 033-2280-1950										
EXTRACT OF AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON 31ST MARCH 2023 (₹ in Lacs)										
PARTICULARS	STANDALONE				CONSOLIDATED					
	Quarter ended (31.03.2023) (Audited)	Quarter ended (31.12.2022) (Unaudited)	Quarter ended (31.03.2022) (Audited)	Year ended (31.03.2023) (Audited)	Year ended (31.03.2022) (Audited)	Quarter ended (31.03.2023) (Unaudited)	Quarter ended (31.12.2022) (Unaudited)	Quarter ended (31.03.2022) (Audited)	Year ended (31.03.2023) (Audited)	Year ended (31.03.2022) (Audited)
Total Income from Operations	2.17	394.05	16.50	1,128.25	657.92	2.17	394.05	16.50	1,095.34	625.01
Net Profit / (Loss) for the period (before tax and Exceptional Items)	(76.22)	329.27	(46.57)	869.48	435.53	(76.22)	329.27	(46.57)	836.57	402.62
Net Profit / (Loss) for the period before tax (after Exceptional Items)	(76.22)	329.27	(46.57)	869.48	435.53	(76.22)	329.27	(46.57)	836.57	402.62
Net Profit / (Loss) for the period after tax	(71.85)	307.83	30.44	753.77	418.64	(71.85)	307.83	30.44	720.86	385.73
Add: Share in Profit/(Loss) of Associate	-	-	-	-	-	351.26	1,142.87	1,076.63	6,321.16	6,917.42
Net Profit / (Loss) after share of Associates	(71.85)	307.83	30.44	753.77	418.64	279.41	1,450.70	1,107.07	7,042.02	7,303.15
Total Comprehensive Income for the period after Tax (Comprising profit for the period and other comprehensive income)	(1,233.71)	1,384.99	(212.24)	152.51	5,442.72	(1,492.64)	3,408.78	670.23	7,206.47	14,970.23
Equity Share Capital	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
Earnings Per Share (of ₹10/- each) *										
Basic (in ₹) :	(7.19)	30.78	3.04	75.38	41.86	27.94	145.07	110.71	704.20	730.32
Diluted (in ₹) :	(7.19)	30.78	3.04	75.38	41.86	27.94	145.07	110.71	704.20	730.32
* Not Annualised										

Note:
The above is an extract of the detailed format of Quarterly and Yearly ended Financial Results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the above Financial Results are available on the Stock Exchange website (www.nseindia.com) and on the Company's website.

By order of the Board
For Naga Dhunseri Group Limited
C.K. DHANUKA
Chairman
DIN: 00005684

Place : Kolkata
Date : The 30th Day of May, 2023

AksharChem (India) Limited				
Regd. Office: "Akshar House", Chhatral Kadi Road, Indrad - 382 715, Mehsana.				
Tel : +91 2764 233007/08/09/10 Fax : +91 2764 233550				
Website: www.aksharchemindia.com, e-mail ID: cs@aksharchemindia.com, CIN: L24110GJ1989PLC012441				
EXTRACT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND FINANCIAL YEAR ENDED MARCH 31, 2023				
Sr. No.	Particulars	Rs. in lakhs except EPS		
		Quarter Ended 31-03-2023	Year Ended 31-03-2023	Quarter Ended 31-03-2022
1.	Total Income from Operations	6,473.83	33,467.86	11,195.63
2.	Net Profit for the period (before tax and exceptional items)	(208.04)	(49.90)	(91.40)
3.	Net Profit for the period before tax (after exceptional items)	(208.04)	(49.90)	(91.40)
4.	Net Profit for the period after tax (after exceptional items)	(196.52)	(94.21)	268.43
5.	Total Comprehensive Income for the period [Comprising Profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	5.85	(1.10)	(10.59)
6.	Paid up Equity Share Capital (Face Value of Rs. 10/- each)	803.31	803.31	803.31
7.	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet	-	27,033.16	-
8.	Earnings per share (for Continuing and discontinued operations)			
	Basic	(2.45)	(1.17)	3.37
	Diluted	(2.45)	(1.17)	3.37

Notes: 1. The above audited financial results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors of the Company in their respective meetings held on May 30, 2023. 2. The above is an extract of the detailed format of Audited Quarter and Year ended Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Audited Quarter and Year ended Financial Results will be available on the Stock Exchange website namely www.bseindia.com and www.nseindia.com and also on the Company's website at www.aksharchemindia.com. 3. The Board of Directors have recommended a final dividend of Rs. 0.50 per equity share (5% of the face value of Rs.10 each) for the financial year ended March 31, 2023 subject to the approval of shareholders at the ensuing Annual General Meeting.

For and on behalf of Board of Directors
AksharChem (India) Limited
Sd/-
Mrs. Paru M. Jaykrishna
Chairperson & Mg. Director

Place: Ahmedabad
Date : May 30, 2023

MARKSANS PHARMA LIMITED							
CIN: L24110MH1992PLC066364							
Registered Office: 11 th Floor, Grandeur, Veera Desai Extension Road, Oshiwara, Andheri [West], Mumbai - 400053.							
Telephone No.: 022-4001 2000, Fax No.: 022-4001 2011, E-mail: info@marksanspharma.com							
STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2023 (₹ in Million)							
Sr. No.	PARTICULARS	STANDALONE				CONSOLIDATED	
		QUARTER ENDED		Current Year ended	Previous Year ended	Current Year ended	Previous Year ended
		31.03.2023	31.03.2022	31.03.2023	31.03.2022	31.03.2023	31.03.2022
1	Total Income from operations	1,573.48	1,839.26	7,156.86	7,005.40	19,114.52	15,326.92
2	Net Profit/(Loss) for the period before Tax	228.45	286.30	1,320.35	1,345.08	3,376.53	2,475.11
3	Net Profit/(Loss) for the period after Tax	178.10	214.27	1,028.66	1,039.88	2,653.21	1,868.14
4	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	171.84	216.20	1,022.75	1,040.34	3,175.32	2,370.97
5	Paid up Equity Share Capital (face value ₹ 1 each fully paid)	453.16	409.31	453.16	409.31	453.16	409.31
6	Earnings per equity share of ₹ 1 each*						
	- Basic	0.43	0.52	2.48	2.54	6.41	4.51
	- Diluted	0.43	0.52	2.48	2.54	6.41	4.51

* EPS is not annualised for the quarter ended 31 March 2023 and 31 March 2022.

Note:
The above is an extract of the detailed format of Audited Financial Results for the Quarter and Year ended 31 March 2023 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of Audited Financial Results are available on www.nseindia.com and www.bseindia.com and Company's website www.marksanspharma.com.

For MARKSANS PHARMA LIMITED
MARK SALDANHA
Chairman & Managing Director
DIN : 00020983

Place: Mumbai
Date : 30 May, 2023
www.marksanspharma.com

The shareholders who have not registered their e-mail addresses are requested to register them with the Company to receive e-communication from the Company. For registering e-mail address, the shareholders are requested to follow the below steps:
i. Shareholders holding shares in physical mode are requested to provide name, folio number, mobile number, e-mail address, scanned copies of self attested share certificate(s) (both sides) copy of PAN/ Aadhaar through e-mail on companysecretary@marksanspharma.com or alternatively, do the same through the Registrar and Transfer Agent's website link at: https://www.bigshareonline.com/InvestorRegistration.aspx.
ii. Shareholders holding shares in dematerialised mode are requested to register their email addresses and mobile numbers with their relevant depositories through their depository participants.

EVEREST KANTO CYLINDER LIMITED					
CIN: L29200MH1978PLC020434					
Registered Office: 204, Raheja Centre, Free Press Journal Marg, 214, Nariman Point, Mumbai 400021 Email: investors@ekc.in;					
Tel Numbers: 022 4926 8300/01 Fax: 022 4926 8354; Website : www.everestkanto.com					
STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2023 (₹ in lakhs, unless otherwise stated)					
Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the Previous Year	Year to date figures for current period ended	Previous Year ended
	31.03.2023	31.12.2022	31.03.2022	31.03.2023	31.03.2022
	Refer note 3	(Unaudited)	Refer note 3	(Audited)	(Audited)
Continuing Operations:					
Total Income from Operations	30,013	25,772	48,619	1,27,995	1,71,244
Net Profit for the period before Tax, Exceptional Items	3,789	319	8,974	11,579	35,989
Net (Loss)/Profit for the period before Tax after Exceptional Items	3,676	(1,675)	8,448	9,472	37,137
Net (Loss)/Profit for the period after Tax	3,625	(1,756)	6,484	7,589	26,453
Discontinued Operations:					
Net Profit for the period before Tax	-	-	-	-	62
Net Profit for the period after Tax	-	-	-	-	62
Net (Loss)/Profit for the period after Tax from Total Operations	3,625	(1,756)	6,484	7,589	26,515
Equity Share Capital	2,244	2,244	2,244	2,244	2,244
Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)				97,662	88,025
Earnings per share (before and after extraordinary items) (face value of ₹ 2/- each)					
Basic and Diluted Earnings per share (not annualised, except for year ended) (in ₹)					
(i) Continuing Operations	3.24	(1.57)	5.78	6.79	23.58
(ii) Discontinued Operations	-	-	-	-	0.06
(iii) Total Operations	3.24	(1.57)	5.78	6.79	23.64

Notes :
1. The above is an extract of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the aforesaid Financial Results is available on the websites of the Stock Exchanges (www.bseindia.com and www.nseindia.com) and on the Company's website (www.everestkanto.com).
2. The above results are reviewed by the Audit Committee and were approved and taken on record by the Board of Directors at its meeting held on 29th May 2023.
3. The figures for the quarter ended 31 March 2023 and 31 March 2022 represent the balancing figures between audited figures in respect of the full financial year and those published till the third quarter of the respective financial year, which were subjected to limited review by statutory auditors.

By the Order of the Board
For Everest Kanto Cylinder Limited
Sd/-
Puneet Khurana
Managing Director
DIN:-00040474

Place : Mumbai
Date : 29th May, 2023

TECHNO ELECTRIC & ENGINEERING COMPANY LIMITED					
(Formerly Simran Wind Project Limited)					
CIN No :L40108UP2005PLC094368					
Corporate Office : " Park Plaza " 71, Park Street, Kolkata - 700 016					
Email : desk.investors@techno.co.in : Website: www.techno.co.in					
Extract of Statement of Consolidated Audited Financial Results for the Quarter and year ended 31 March, 2023 (₹ in Lakhs)					
PARTICULARS	Quarter ended			Year ended	
	31 March 2023	31 December 2022	31 March 2022	31 March 2023	31 March 2022
	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)
Total income from operations (net)	31297.06	18525.69	30521.78	82949.85	99916.80
Net Profit / (Loss) for the period / year from continuing operations (before Tax, Exceptional and/or Extraordinary items)	1752.92	3974.78	4008.62	13904.38	29856.82
Net Profit / (Loss) for the period/ year from Discontinued operations (before Tax, Exceptional and/or Extraordinary items)	-144.80	119.32	-972.10	4541.05	2719.67
Net Profit / (Loss) for the period / year from continuing operations before tax (after Exceptional and/or Extraordinary items)	1752.92	3974.78	4008.62	13904.38	29856.82
Net Profit / (Loss) for the period / year from discontinued operations before tax (after Exceptional and/or Extraordinary items)	-144.80	119.32	-972.10	11326.66	2719.67
Net Profit / (Loss) for the period / year from continuing operations after Tax (after Exceptional and /or Extraordinary items)	110.55	3154.90	4423.10	9259.63	23939.62
Net Profit / (Loss) for the period / year from discontinued operations after Tax (after Exceptional and /or Extraordinary items)	5567.24	-13.76	-716.20	9024.95	2083.50
Net Profit / (Loss) for the period from discontinued operations after Tax (after Exceptional and /or Extraordinary items)	6785.61	0.00	0.00	6785.61	0.00
Total Comprehensive Income for the year	5357.01	3413.59	3962.44	18178.09	26264.33
Equity Share Capital	2,152.38	2,164.75	2,200.00	2,152.38	2,200.00
Other Equity (excluding Revaluation Reserves)				191912.1846	181475.74
Earnings Per Share (After tax and before Exceptional items) (of ₹ 2/- each) for continuing operations					
Basic :	0.10	2.91	4.04	8.49	21.43
Diluted:	0.10	2.91	4.04	8.49	21.43
Earnings Per Share (After tax and before Exceptional items) (of ₹ 2/- each) for discontinued operations					
Basic :	5.17	(0.01)	(0.65)	8.28	1.89
Diluted:	5.17	(0.01)	(0.65)	8.28	1.89
Earnings Per Share (After tax and before Exceptional items) (of ₹ 2/- each) for continuing and discontinued operations					
Basic :	5.28	2.89	3.38	16.77	23.33
Diluted:	5.28	2.89	3.38	16.77	23.33

Key numbers of Standalone Financial Results:

PARTICULARS	Quarter ended			Year ended	
	31 March 2023	31 December 2022	31 March 2022	31 March 2023	31 March 2022
	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)
Total income from operations (net)	45,009.30	18,525.69	30,521.78	96,662.09	99,916.80
Profit before Tax for the period from continuing operations	5,275.42	3,964.13	4,076.62	17,485.38	29,915.10
Profit before Tax for the period from discontinued operations	(144.80)	119.32	(972.10)	4,541.05	2,719.67
Net Profit after Tax for the period from continuing operations	3,621.75	3,146.05	4,442.84	12,812.53	23,950.84
Net Profit after Tax for the period from discontinued operations	5,567.24	(13.76)	(716.20)	9,024.95	2,083.50

Note : The above is an extract of the detailed format of Financial Results for the Quarter and year ended March 31, 2023 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the Stock Exchange websites, www.nseindia.com and www.bseindia.com and on the Company's website www.techno.co.in.

For and on behalf of the Board of Directors
(P. P. Gupta)
Managing Director
(DIN: 00055954)

Date : The 29 May, 2023

